Healthcare - Industry centre - Yahoo Finance

UK Markets close in 1 hr 6 mins
Loading...
  • NVS
    American City Business Journals20 minutes ago

    Cambridge-based Ionis spinout Akcea plots $100M IPO

    Akcea Therapeutics, a Cambridge-based subsidiary of Ionis Pharmaceuticals developing treatments for lipid disorders, said Monday that it plans to raise up to $100 million in an initial public offering. The 26-employee company said in a federal filing that it had applied to list its stock on the Nasdaq under the symbol “AKCA.” It would be the second Massachusetts-based biotech to go public so far in 2017, after Cambridge cancer drug developer Jounce Therapeutics (JNCE). A $100 million IPO would also be one of the largest offerings for a local biotech in recent memory.

  • 3 Big Pharma Stocks You Don't Have to Babysit
    JNJ
    Motley Fool23 minutes ago

    3 Big Pharma Stocks You Don't Have to Babysit

    No tending needed for big pharma stocks Johnson & Johnson, Pfizer, and Novartis.

  • NVS
    Market Realist1 hour ago

    Novartis’s Innovative Medicines Segment in 2016

    Novartis’s Innovative Medicines segment, formerly referred to as its Pharmaceuticals segment, consists of products for therapeutic areas including oncology, respiratory, and established medicines.